Northwestern Mutual Wealth Management Co. Sells 311,614 Shares of Pfizer Inc. $PFE

Key Points

• Northwestern Mutual Wealth Management Co. has decreased its stake in Pfizer by 29.9%, selling 311,614 shares to hold a total of 729,412 shares, valued at approximately $18.48 million.
• Several institutional investors have recently changed their positions in Pfizer, with new investments totaling around $27,000 to $28,000 from firms such as Clarity Asset Management and North Capital.
• Pfizer reported a Q2 earnings per share of $0.78, exceeding expectations, and set a FY 2025 EPS guidance of 2.900-3.100, showing growth potential despite varying analyst ratings.

Northwestern Mutual Wealth Management Co. decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 29.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 729,412 shares of the biopharmaceutical company's stock after selling 311,614 shares during the period. Northwestern Mutual Wealth Management Co.'s holdings in Pfizer were worth $18,483,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Clarity Asset Management Inc. bought a new position in Pfizer in the 4th quarter valued at approximately $27,000. Gould Capital LLC lifted its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in Pfizer in the 1st quarter valued at approximately $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter valued at approximately $28,000. Finally, Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter valued at approximately $28,000. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PFE shares. Leerink Partners dropped their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Morgan Stanley raised their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank dropped their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. HSBC dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, The Goldman Sachs Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

PFE stock opened at $25.15 on Tuesday. The stock has a 50-day moving average price of $24.72 and a 200-day moving average price of $24.39. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market cap of $142.99 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm posted $0.60 earnings per share. The business's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.